Aptuit and Axxam form alliance for integrated drug discovery services
They have already begun a major integrated discovery programme for a large pharma company
Aptuit, a global drug discovery and development contract research organisation (CRO), is joining up with Axxam, an Italian discovery company with expertise in target biology and early phase discovery solutions, to provide integrated services from gene to high-quality candidates and beyond.
The firms say the partnership has already resulted in the commencement of their first significant joint integrated project with a large pharma company.
Jonathan Goldman, Chief Executive of Aptuit, based in Greenwich, CT, in the US, said: 'We serve biopharmaceutical companies in the discovery of small molecules in a broad range of therapeutic areas including neuroscience, oncology, infectious disease, inflammation, respiratory and others. Our alliance with Axxam is part of our growth strategy.'
He added that the partnership broadens Aptuit's capabilities by enhancing its hit identification, validation and expansion services.
'Expected benefits include increased probability of successful IND candidate nomination, reduced timeline and reduced cost,' said Goldman.
Stefan Lohmer, Co-founder and Chief Executive of Axxam, based in Milan, added: 'This alliance will allow some of our customers to leverage our deep expertise in target biology, assay development and high throughput screening even further.'